NCT03430518 is a Phase 1 clinical trial of Durvalumab in HER2-Negative Metastatic Breast Cancer, sponsored by Amy Tiersten.

Who is sponsoring NCT03430518?

NCT03430518 is sponsored by Amy Tiersten.

What drugs are being tested in NCT03430518?

Interventions in NCT03430518: Durvalumab, Eribulin.

What condition does NCT03430518 study?

NCT03430518 studies HER2-Negative Metastatic Breast Cancer, Recurrent Ovarian Cancer.

Is NCT03430518 still recruiting?

NCT03430518 is currently completed. Last updated 5 August 2020.

Last reviewed 2020-08-05 · How we verify

NCT03430518

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

Completed Phase 1 Last updated 5 August 2020

What this trial tests

Phase 1 trial testing Durvalumab in HER2-Negative Metastatic Breast Cancer in 9 participants. Completed in 10 February 2020.

Timeline

17 May 2018

Primary endpoint
10 February 2020

10 February 2020

Quick facts

Lead sponsor	Amy Tiersten
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	17 May 2018
Primary completion	10 February 2020
Estimated completion	10 February 2020
Sites	1 location across United States

Drugs / interventions tested

Durvalumab — full drug profile →
Eribulin (ERIBULIN) — full drug profile →

Conditions studied

HER2-Negative Metastatic Breast Cancer — all drugs for HER2-Negative Metastatic Breast Cancer →
Recurrent Ovarian Cancer — all drugs for Recurrent Ovarian Cancer →

Sponsor

Amy Tiersten

Who can join

18 and older, any sex, with HER2-Negative Metastatic Breast Cancer or Recurrent Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the recommended Phase 2 combination dose (RP2D) of eribulin with durvalumab.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Wu M, Huang Q, Xie Y, Wu X, et al · · 2022 · cited 336× · PMID 35279217 · DOI 10.1186/s13045-022-01242-2
Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy.
Yang Y, Yang Y, Yang J, Zhao X, et al · · 2020 · cited 168× · PMID 32850861 · DOI 10.3389/fcell.2020.00758
Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.
Maiorano BA, Maiorano MFP, Lorusso D, Maiello E. · · 2021 · cited 60× · PMID 34503248 · DOI 10.3390/cancers13174438
Photodynamic Therapy and Hyperthermia in Combination Treatment-Neglected Forces in the Fight against Cancer.
Bienia A, Wiecheć-Cudak O, Murzyn AA, Krzykawska-Serda M. · · 2021 · cited 36× · PMID 34452108 · DOI 10.3390/pharmaceutics13081147
Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer.
Kaur P, Porras TB, Ring A, Carpten JD, et al · · 2019 · cited 20× · PMID 30728399 · DOI 10.1038/s41598-018-37574-8
Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed.
Hu X, Bian C, Zhao X, Yi T. · · 2022 · cited 19× · PMID 36275669 · DOI 10.3389/fimmu.2022.1034903
Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer.
Huang X, Li XY, Shan WL, Chen Y, et al · · 2023 · cited 14× · PMID 37033645 · DOI 10.3389/fphar.2023.1131342

Verify or expand the search:

Other trials of Durvalumab

Trials testing the same drug.

NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting

Other Amy Tiersten trials

Trials by the same sponsor.

NCT02531932 — Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Tr · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03430518 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amy Tiersten
Last refreshed: 5 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03430518.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing